We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
+0.8%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$796M
AUM Growth
-$185M
Cap. Flow
-$163M
Cap. Flow %
-20.42%
Top 10 Hldgs %
3.37%
Holding
1,987
New
622
Increased
338
Reduced
393
Closed
624

Top Sells

Rank Stock Value
1
MS icon
Morgan Stanley
MS
+$5.34M
2
MSFT icon
Microsoft
MSFT
+$5.22M
3
OPLN
Openlane
OPLN
+$4.6M
4
AAPL icon
Apple
AAPL
+$4.51M
5
HRI icon
Herc Holdings
HRI
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 16.45%
2 Industrials 15.7%
3 Technology 14.88%
4 Consumer Discretionary 11.13%
5 Financials 10.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VKTX icon
826
Viking Therapeutics
VKTX
$4B
$353K 0.04%
76,700
+23,122
+43% +$130K
VVX icon
827
V2X
VVX
$2.65B
$353K 0.04%
+7,718
New +$366K
ORIC icon
828
Oric Pharmaceuticals
ORIC
$1.4B
$352K 0.04%
+23,954
New +$374K
VST icon
829
Vistra
VST
$47.4B
$352K 0.04%
15,458
-253
-2% -$5.07K
GOOD
830
Gladstone Commercial Corp
GOOD
$627M
$351K 0.04%
+13,628
New +$309K
APPS icon
831
Digital Turbine
APPS
$1.74B
$350K 0.04%
+5,739
New +$390K
AVAV icon
832
AeroVironment
AVAV
$9.45B
$350K 0.04%
+5,646
New +$459K
CINF icon
833
Cincinnati Financial
CINF
$27.1B
$350K 0.04%
+3,071
New +$363K
CRNX icon
834
Crinetics Pharmaceuticals
CRNX
$8.92B
$350K 0.04%
12,335
-4,145
-25% -$102K
OGE icon
835
OGE Energy
OGE
$9.71B
$349K 0.04%
9,092
-40,945
-82% -$1.43M
ANIK icon
836
Anika Therapeutics
ANIK
$287M
$348K 0.04%
9,717
-9,704
-50% -$388K
CSV icon
837
Carriage Services
CSV
$569M
$348K 0.04%
5,404
-11,976
-69% -$620K
FORM icon
838
FormFactor
FORM
$9.17B
$348K 0.04%
+7,619
New +$312K
RYZ
839
Ryerson Holding Corp
RYZ
$1.46B
$348K 0.04%
13,354
+1,101
+9% +$27.7K
BOC icon
840
Boston Omaha
BOC
$436M
$347K 0.04%
+12,061
New +$394K
CACC icon
841
Credit Acceptance
CACC
$6.08B
$347K 0.04%
+504
New +$324K
TCRR
842
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$347K 0.04%
74,402
+823
+1% +$5.14K
EVFM
843
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$347K 0.04%
61,652
+57,627
+1,432% +$490K
AMG icon
844
Affiliated Managers Group
AMG
$9.76B
$346K 0.04%
+2,106
New +$353K
IMVT icon
845
Immunovant
IMVT
$8.25B
$346K 0.04%
40,654
-40,516
-50% -$334K
SITC icon
846
SITE Centers
SITC
$165M
$345K 0.04%
+27,945
New +$351K
SNEX icon
847
StoneX
SNEX
$7.94B
$344K 0.04%
28,401
-18,209
-39% -$239K
IGM icon
848
iShares Expanded Tech Sector ETF
IGM
$10.7B
$343K 0.04%
4,692
-1,170
-20% -$84.1K
VRTX icon
849
Vertex Pharmaceuticals
VRTX
$126B
$343K 0.04%
1,564
-895
-36% -$174K
VV icon
850
Vanguard Morningstar Large-Cap ETF
VV
$54.3B
$343K 0.04%
1,553
-510
-25% -$109K

Similar funds

GSA Capital Partners's Q4 2021 Portfolio in Review

As of Q4 2021, GSA Capital Partners held 1,987 positions worth $796M, down 19% from $982M the previous quarter. Its ten largest holdings account for 3.4% of the portfolio.

GSA Capital Partners withdrew a net $163M in Q4 2021, closing 624 positions and reducing 393 holdings. Its most notable exit was Morgan Stanley, an estimated $5.34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Technology.

Against the trend, GSA Capital Partners opened a new position in Genius Sports worth $2.45M.

  • GSA Capital Partners's largest Q4 2021 buy was Genius Sports: 322,717 shares worth $2.45M.
  • GSA Capital Partners added most to State Street Consumer Staples Select Sector SPDR ETF in Q4 2021, an estimated $2.43M increase.
  • GSA Capital Partners's biggest Q4 2021 reduction was Microsoft, cutting an estimated $5.22M.
  • GSA Capital Partners fully exited Morgan Stanley in Q4 2021, selling an estimated $5.34M.
  • GSA Capital Partners's ten largest holdings make up 3.4% of its $796M portfolio in Q4 2021.
  • GSA Capital Partners opened 622 new positions and closed 624 in Q4 2021.
  • GSA Capital Partners's portfolio value fell 19% quarter-over-quarter to $796M.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.